Fmr LLC Grows Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

FMR LLC lifted its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 1,711.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,634,231 shares of the company's stock after acquiring an additional 10,047,329 shares during the period. FMR LLC owned 14.01% of Nurix Therapeutics worth $200,349,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the company. Lord Abbett & CO. LLC acquired a new stake in shares of Nurix Therapeutics in the third quarter valued at approximately $7,879,000. Vanguard Group Inc. grew its holdings in Nurix Therapeutics by 8.3% in the 4th quarter. Vanguard Group Inc. now owns 4,345,266 shares of the company's stock valued at $81,865,000 after buying an additional 333,452 shares in the last quarter. Norges Bank acquired a new stake in shares of Nurix Therapeutics in the 4th quarter worth $6,006,000. Nikko Asset Management Americas Inc. raised its holdings in shares of Nurix Therapeutics by 42.8% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 789,222 shares of the company's stock worth $14,869,000 after acquiring an additional 236,620 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Nurix Therapeutics by 42.7% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 789,222 shares of the company's stock valued at $14,869,000 after acquiring an additional 235,971 shares during the last quarter.

Nurix Therapeutics Price Performance

Shares of NRIX stock traded up $0.44 during trading hours on Friday, reaching $10.24. 1,322,027 shares of the stock were exchanged, compared to its average volume of 887,503. The business's fifty day moving average is $13.32 and its two-hundred day moving average is $18.85. The firm has a market capitalization of $780.66 million, a P/E ratio of -3.54 and a beta of 2.23. Nurix Therapeutics, Inc. has a 12-month low of $8.18 and a 12-month high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its quarterly earnings data on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, beating analysts' consensus estimates of ($0.72) by $0.05. The company had revenue of $18.45 million for the quarter, compared to the consensus estimate of $12.78 million. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. During the same period in the prior year, the firm posted ($0.76) EPS. As a group, equities research analysts predict that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Insider Buying and Selling at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 2,811 shares of the firm's stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $55,798.35. Following the sale, the chief financial officer now owns 39,549 shares of the company's stock, valued at approximately $785,047.65. This trade represents a 6.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Gwenn Hansen sold 3,690 shares of the company's stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $73,246.50. Following the completion of the transaction, the insider now directly owns 55,937 shares of the company's stock, valued at $1,110,349.45. This trade represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 12,326 shares of company stock worth $213,449 over the last ninety days. Corporate insiders own 7.20% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Stephens restated an "overweight" rating and set a $31.00 price objective on shares of Nurix Therapeutics in a research report on Tuesday, January 21st. Needham & Company LLC decreased their price objective on Nurix Therapeutics from $28.00 to $27.00 and set a "buy" rating on the stock in a report on Wednesday, April 9th. JPMorgan Chase & Co. cut their target price on Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating for the company in a research note on Wednesday, January 29th. Stifel Nicolaus decreased their price target on Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating on the stock in a research note on Wednesday, April 9th. Finally, Morgan Stanley raised their price objective on Nurix Therapeutics from $16.00 to $17.00 and gave the stock an "equal weight" rating in a research report on Monday, February 3rd. Three research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $30.44.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.